<DOC>
	<DOCNO>NCT00526448</DOCNO>
	<brief_summary>To compare sustained virological response ( SVR = ribonucleic acid ( RNA ) - hepatitis C virus ( HCV ) undetectable week 24 end treatment ) chronic hepatitis C patient genotype 1-4 co-infected HIV-HCV , treat Peginterferón alfa-2a ( 40 KD ) 180 µg/week Ribavirin ( 2000 mg/day 4 week , follow 1000-1200 mg/day , accord body weight ) ; versus Peginterferón alfa-2a ( 40 KD ) 180 μg/week Ribavirin ( 1000-1200 mg/day , accord body weight ) . To evaluate impact extend treatment Peginterferon alfa-2a Ribavirin week 72 , SVR patient genotypes 1-4 without rapid virological response ( RVR = RNA - HCV undetectable 4 week ) .</brief_summary>
	<brief_title>Phase IV Study Evaluate Efficacy/Safety Extend Treatment High Dose Ribavirin co-Infected Patients</brief_title>
	<detailed_description>The PRESCO study ( ribavirin dose 1000-1200 mg/day ) emphasize optimal ribavirin exposure seem crucial maximize sustain virological response minimize incidence relapse treatment discontinuation . Recent report show beneficial extend treatment duration patient without rapid virological response 4 week ( RNA-HCV &lt; 50 UI/ml ) .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female patient &gt; 18 year age Serologic evidence antiHCV Detectable plasma HCVRNA Serologic evidence HIV1 infection CD4 cell count &gt; /= 250 cell/mm3 Stable status HIV1 infection opinion investigator Patients stable antiretroviral therapy ( HAART ) least 6 week prior baseline whose HAART regimen ( drug dosage ) expect remain unaltered first 6 week study Patients HAART least 6 week prior randomization willing delay initiation HAART therapy least 6 week Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug Willingness give write informed consent Women ongoing pregnancy breast feed Male partner woman pregnant IFN/ribavirin therapy previous time Child Pugh &gt; 6 ( Child Pugh B C ) History condition consistent decompensated liver disease Any investigational drug 6 week prior first dose study drug ( expanded access program HIV treatment allow ) Patients treated didanosine and/or zidovudine Positive test antiHAV IgM Ab , HBsAg , antiHBc IgM Ab , HBeAg History evidence medical condition associate chronic liver disease HCV Hepatocarcinoma observe liver ecography Serum concentration ceruloplasmin alfa1antitrypsin screen consistent increase risk metabolic liver disease Active HIVrelated opportunistic infection and/or malignancy require acute systemic therapy Absolute neutrophil count ( ANC ) &lt; 1500 cells/mm3 Hgb &lt; 11 g/dL woman 12 g/dL men patient anemia would medically problematic Hemoglobinopathy cause tendency hemolysis Platelet count &lt; 50,000 cells/mm3 History GCSF , GMCSF epo treatment 3 month prior first dose study drug Serum creatinine level &gt; 1.5 time upper limit normal screen History severe psychiatric disease , especially depression History severe seizure disorder current anticonvulsant use History immunologically mediate disease History evidence chronic pulmonary disease associate functional limitation History significant cardiac disease could worsen acute anemia History thyroid disease poorly control prescribed medication Evidence severe retinopathy History major organ transplantation exist functional graft History evidence severe illness , malignancy condition would make patient , opinion investigator , unsuitable study History systemic antineoplastic immunomodulatory treatment 6 month prior first dose study drug expectation treatment need time study Concomitant medication rifampin/rifampicin , rifabutin , pyrazinamide , isoniazid , gancyclovir , thalidomide , oxymetholone , immunomodulatory treatment systemic antiviral agent adjuvant therapy CHC Drug use within 6 month 1st dose excessive alcohol consumption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>high dose ribavirin</keyword>
	<keyword>extend treatment duration</keyword>
	<keyword>tailor treatment</keyword>
</DOC>